[Pharmacokinetics and biodistribution of 3H-norcantharidin in mice]
- PMID: 17703775
[Pharmacokinetics and biodistribution of 3H-norcantharidin in mice]
Abstract
A single dose of 3H-norcantharidin solution was intragastrically given, blood, tissues, urine and feces were collected as scheduled, and radioactivity in these samples was determined by tritium tracing method to investigate the pharmacokinetics, tissue distribution and excretion of norcantharidin in Kunming mice. The pharmacokinetic characteristics of norcantharidin were evaluated by DAS version 2.0. The blood concentration reached to maximum 0. 5 h after intragastric administration. The radioactivity in tissues was high in small intestine, gallbladder, stomach, adrenal gland, kidney, heart and uterus 15 minutes after administration, descending with time, and high in gallbladder, adrenal gland and uterus 3 hours post dosing. The 24 h accumulative excretion ratio of urine and feces were 65.40% and 1.33% respectively. 3H-norcantharidin was easily absorbed after orally given to mice, the radioactivity was high and existed for a long-time in gallbladder, adrenal gland and uterus, and low but also existed for a long-time in large intestine, thymus and fat tissue. 3H-norcantharidin was declined quickly in small intestine, stomach, kidney and heart, and occurred rarely in brain. Norcantharidin was excreted mainly by urinary route and seldom in feces, which may be the cause of the urinary stimulation side effects observed. Because the radioactivity measured were the sum of 3H labeled norcantharidin and its metabolites, further studies on the disposition of norcantharidin in mammal animals, on the separation or identification of metabolites and, if any, on their activities, are fairly needed.
Similar articles
-
Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS.Int J Nanomedicine. 2012;7:1723-35. doi: 10.2147/IJN.S29696. Epub 2012 Apr 2. Int J Nanomedicine. 2012. PMID: 22619523 Free PMC article.
-
Determination of norcantharidin in mouse tissues by liquid chromatography coupled to tandem mass spectrometry and its tissue distribution study.Arzneimittelforschung. 2012 Jun;62(6):290-4. doi: 10.1055/s-0032-1308980. Epub 2012 Apr 2. Arzneimittelforschung. 2012. PMID: 22473525
-
Comparative tissue distribution and excretion of orally administered [3H]diacetoxyscirpenol (anguidine) in rats and mice.Toxicol Appl Pharmacol. 1990 May;103(3):430-40. doi: 10.1016/0041-008x(90)90316-m. Toxicol Appl Pharmacol. 1990. PMID: 2339416
-
Norcantharidin analogues: a patent review (2006 - 2010).Expert Opin Ther Pat. 2011 Nov;21(11):1743-53. doi: 10.1517/13543776.2011.629190. Expert Opin Ther Pat. 2011. PMID: 22017412 Review.
-
Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.Arzneimittelforschung. 2001 Sep;51(9):699-725. doi: 10.1055/s-0031-1300105. Arzneimittelforschung. 2001. PMID: 11642003 Review.
Cited by
-
Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.Chin Med. 2020 May 29;15:55. doi: 10.1186/s13020-020-00338-6. eCollection 2020. Chin Med. 2020. PMID: 32514288 Free PMC article. Review.
-
Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action.Cytotechnology. 2009 Apr;59(3):201-8. doi: 10.1007/s10616-009-9210-3. Epub 2009 Jul 15. Cytotechnology. 2009. PMID: 19603282 Free PMC article.
-
Inhibitory effects of norcantharidin against human lung cancer cell growth and migration.Cytotechnology. 2010 Aug;62(4):349-55. doi: 10.1007/s10616-009-9250-8. Epub 2010 Jan 20. Cytotechnology. 2010. PMID: 20087654 Free PMC article.
-
Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer.World J Gastroenterol. 2021 Jul 14;27(26):4208-4220. doi: 10.3748/wjg.v27.i26.4208. World J Gastroenterol. 2021. PMID: 34326620 Free PMC article.
-
Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS.Int J Nanomedicine. 2012;7:1723-35. doi: 10.2147/IJN.S29696. Epub 2012 Apr 2. Int J Nanomedicine. 2012. PMID: 22619523 Free PMC article.